Drug Trial Radar · NCT06132893
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Mar 14, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Conditions
- Focal Epilepsy
Interventions
BHV-7000Drug
BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
BHV-7000Drug
BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
PlaceboDrug
Matching placebo taken once daily
BHV-7000Drug
BHV-7000 75 mg. Participants willtake blinded investigational product(IP) once daily
PlaceboDrug
Matching placebo taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part B: Change from Baseline in 28-day average seizure frequencyTime frame: Baseline, Week 8 to Week 20 of Part B
- Part A: Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEsTime frame: Week 8 to Week 20 of Part A
- Part A: Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Week 8 to Week 20 of Part A
Locations
104 sites in 12 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Center for Neurosciences
Tucson, Arizona
Clinical Trials, Inc.
Little Rock, Arkansas
University of California San Diego
La Jolla, California
University of California, Los Angeles
Los Angeles, California
Stanford Health Care
Palo Alto, California
Profound Research LLC
Pasadena, California
University of Colorado Anschultz Medical Campus
Aurora, Colorado
Yale School of Medicine - Yale-New Haven Hospital
New Haven, Connecticut
EZR Research LLC
Boca Raton, Florida
Nova Clinical Research, LLC
Bradenton, Florida
University of Florida (Jacksonville)
Jacksonville, Florida
University of Miami
Miami, Florida
Medsol Clinical Research Center
Port Charlotte, Florida
Santos Research Center
Tampa, Florida
Encore Medical Research of Weston LLC.
Weston, Florida
Augusta University
Augusta, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho
Northwestern University
Chicago, Illinois
Revive Research Institute, Inc.
Elgin, Illinois
Bluegrass Epilepsy Research
Lexington, Kentucky
MAESC
Bethesda, Maryland
Javara
Silver Spring, Maryland
Minnesota Epilepsy Group, P.A.
Roseville, Minnesota
Washington University School of Medicine
St Louis, Missouri
NEREG
Hackensack, New Jersey
Inst of Neurology
Livingston, New Jersey
Dent Neurosciences Research Center
Amherst, New York
BCHP
Hawthorne, New York
Northwell Health
New York, New York
Stony Brook Medicine
Stony Brook, New York
Five Towns Neuroscience Research
Woodmere, New York
Wake Forest Baptist
Winston-Salem, North Carolina
NeuroScience Research Center
Canton, Ohio
University of Cincinnati
Cincinnati, Ohio
OSU
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
UPMC
Pittsburgh, Pennsylvania
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.